Mounjaro price hike drives patients to stock up

UK patients rush to secure tirzepatide as prices may jump above £300 a month, prompting warnings from pharmacists and calls for guidance.

Mounjaro price hike drives patients to stock up

Pharmacies in the United Kingdom report a surge of calls from patients hoping to secure tirzepatide, sold as Mounjaro, as prices look set to rise. If the monthly cost climbs above £300 from September, many private patients could see a sharp jump from current prices. Pharmacists warn that bulk buying is neither possible nor safe and urge patients to speak with a local pharmacist.

The shift comes as Wegovy, a rival drug, appears not to raise its price. Some patients may switch if affordability becomes a concern, while others expect ongoing frustration over access. Boots has said it will review its weight loss services in light of the change, and health workers remind people to avoid unverified sellers selling cheaper options online.

The price movement shows how access to costly weight loss therapies in the private market depends on price signals and consumer confidence. When tirzepatide becomes less affordable, patients either seek alternatives or pause treatment, which can widen health disparities. The competition between Mounjaro and Wegovy adds a layer of strategic pricing that could influence patient choices in the near term.

Experts say the situation calls for calm, clear guidance, and attention from policymakers on affordability and access. Pharmacies serve as gatekeepers during price shocks, underscoring the need for reliable information about dosing, safety, and what to do if a treatment becomes financially out of reach.

Highlights

The next weeks will test how price shifts affect real lives.